Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · IEX Real-Time Price · USD
34.95
-0.65 (-1.83%)
May 17, 2024, 4:00 PM EDT - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 41.1, with a low estimate of 24 and a high estimate of 56. The average target predicts an increase of 17.60% from the current stock price of 34.95.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for KYMR stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 4 | 3 |
| Hold | 4 | 4 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 11 | 11 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $53 → $52 | Buy | Maintains | $53 → $52 | +48.78% | May 3, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $53 | Buy | Initiates | $53 | +51.65% | Apr 22, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $41 → $54 | Strong Buy | Maintains | $41 → $54 | +54.51% | Mar 1, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $39 → $56 | Buy | Maintains | $39 → $56 | +60.23% | Feb 27, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $34 → $47 | Buy | Maintains | $34 → $47 | +34.48% | Feb 23, 2024 |
Financial Forecast
Revenue This Year
59.85M
from 78.59M
Decreased by -23.84%
Revenue Next Year
74.24M
from 59.85M
Increased by 24.04%
EPS This Year
-3.13
from -2.52
EPS Next Year
-3.30
from -3.13
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 131.3M | 135.6M | 284.6M | 834.8M | 1.1B |
| Avg | 59.9M | 74.2M | 71.9M | 139.9M | 259.6M |
| Low | 14.9M | 19.6M | n/a | -39.2M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 67.0% | 126.5% | 283.3% | 1,061.1% | 713.4% |
| Avg | -23.8% | 24.0% | -3.2% | 94.6% | 85.5% |
| Low | -81.0% | -67.3% | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.72 | -2.01 | -1.62 | 4.04 | 6.03 |
| Avg | -3.13 | -3.30 | -3.55 | -2.98 | -1.82 |
| Low | -4.08 | -4.47 | -5.29 | -4.71 | -3.96 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.